Anti-LINGO-1 has no detectable immunomodulatory effects in preclinical and phase 1 studies

201730 citationsJournal Articlegold Open Access

Authors

Ann Ranger · IMMUNOe Research Center

Soma Ray · IMMUNOe Research Center

Suzanne Szak · Biogen (United States)

Andrea Dearth · IMMUNOe Research Center

Norm Allaire · IMMUNOe Research Center

Ronald S. Murray · IMMUNOe Research Center

Rebecca Gardner ·

Abstract

This study provides Class II evidence that in patients with MS, opicinumab does not have immunomodulatory effects detected by changes in immune gene transcript expression.

Topics & Keywords

T-cell and B-cell Immunology Immunotherapy and Immune Responses Immune Response and Inflammation

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Neurology Neuroimmunology & Neuroinflammation

Volume 5, Issue 1, pp. e417-e417

DOI: 10.1212/nxi.0000000000000417

Field-Weighted Citation Impact: 1.79